@article{1a48f4556aec491cb0b35478fff58de5,
title = "Alemtuzumab CARE-MS I 5-year follow-up: Durable efficacy in the absence of continuous MS therapy",
keywords = "MULTIPLE-SCLEROSIS PATIENTS, CONTROLLED PHASE-3 TRIAL, LONG-TERM DISABILITY, BRAIN ATROPHY, INTERFERON-BETA",
author = "Eva Havrdova and Arnold, {Douglas L.} and Cohen, {Jeffrey A.} and Hans-Peter Hartung and Fox, {Edward J.} and Gavin Giovannoni and Sven Schippling and Selmaj, {Krzysztof W.} and Anthony Traboulsee and Compston, {D. Alastair S.} and Margolin, {David H.} and Karthinathan Thangavelu and Rodriguez, {Claudio E.} and Darlene Jody and Hogan, {Richard J.} and Panos Xenopoulos and Panzara, {Michael A.} and {CARE-MS I CAMMS03409 Investigators} and Raymond Hupperts and Coles, {Alasdair J.}",
year = "2017",
month = sep,
day = "12",
doi = "10.1212/WNL.0000000000004313",
language = "English",
volume = "89",
pages = "1107--1116",
journal = "Neurology",
issn = "0028-3878",
publisher = "LIPPINCOTT WILLIAMS & WILKINS",
number = "11",
}